Development

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Articles

An increase in applications for gene therapies is putting stress on FDA’s resources.

FDA Eyes New Strategies to Spur Gene Therapy Development

Feliza Mirasol is the science editor for 

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site

Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.

EMA Accepts MAAs from Sandoz for Proposed Denosumab Biosimilar

With $73 million in financing from investment firms, Myeloid Therapeutics plans to accelerate its lead clinical candidate into Phase I/II development for treating solid tumors.

Myeloid Therapeutics Gets $73 Million to Advance mRNA-based Pipeline

Sania Therapeutics has emerged from stealth mode and launched its technology platforms for enabling the development of novel therapeutics to treat neural circuit dysfunction.

Launch of Sania Therapeutics Expected to Advance Development of Novel Therapeutics for Neural Circuit Dysfunction

Under the collaboration, BiOneCure Therapeutics and Nanjing Leads Biolabs intend to develop a range of innovative antibody-drug conjugates for treating solid tumors.

BiOneCure Therapeutics and Nanjing Leads Biolabs Partner to Develop ADCs for Solid Tumors

Brian Huber is vice-president of Therapeutic Areas, Drug Development, and Consulting at ICON.

Tamie Joeckel is global business lead of the Cell and Gene Therapy Group at ICON.

The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.

Challenges of Expanding CAR-T Cell Therapy into Solid Tumors

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Lipids aren’t the only important ingredients influencing stability and in vivo performance.

Stability in mRNA-LNP Formulations

The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

Chris Spivey is the editorial director of 

Actions combatting the next pandemic must be diverse, reliable, and sustainable.

Biologics APIs